• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Midatech Pharma PLC American Depositary Shs

    1/8/24 4:01:05 PM ET
    $MTP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTP alert in real time by email
    SC 13G 1 mercer_13g.htm SCHEDULE 13G

     

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    Biodexa Pharmaceuticals PLC
    (Name of Issuer)
     
    Ordinary shares, nominal value £0.001 per share
    (Title of Class of Securities)
     
    59564R708**
    (CUSIP Number)
     
    December 21, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    ** There is no CUSIP number assigned to the Ordinary Shares. The CUSIP number 59564R708 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on The Nasdaq Capital Market under the symbol “BDRX.” Each ADS represents 400 Ordinary Shares.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities and Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     
     

     

     

    CUSIP No.  59564R708   13G   Page 2 of 5 Pages

     

    1  NAME OF REPORTING PERSONS
       
      MERCER STREET GLOBAL OPPORTUNITY FUND, LLC
    2 CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP
     

     

    (a)  ☐

      (b)  ☐
    3 SEC USE ONLY
       
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware
      5                  SOLE VOTING POWER
         
        109,396,800 Ordinary Shares (represented by 273,492 ADSs) (including 46,900,000 Ordinary Shares (represented by 117,250 ADSs) issuable upon the exercise of warrants)* (see Item 4)
    NUMBER OF 6 SHARED VOTING POWER
    SHARES    
    BENEFICIALLY    0
    OWNED BY 7 SOLE DISPOSITIVE POWER
    EACH REPORTING    
    PERSON WITH   109,396,800 Ordinary Shares (represented by 273,492 ADSs) (including 46,900,000 Ordinary Shares (represented by 117,250 ADSs) issuable upon the exercise of warrants)* (see Item 4)
      8 SHARED DISPOSITIVE POWER
         
        0
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      109,396,800 Ordinary Shares (represented by 273,492 ADSs) (including 46,900,000 Ordinary Shares (represented by 117,250 ADSs) issuable upon the exercise of warrants)* (see Item 4)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     

     

    ☐

    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      9.99% *
    12 TYPE OF REPORTING PERSON
     

     

    OO

           

     

      

    * As more fully described in Item 4, the Reporting Person holds warrants subject to a 9.99% beneficial ownership blocker. The percentage set forth on row (11) and the number of Ordinary Shares set forth on rows (6), (8) and (9) give effect to such blocker.

     

     

     
     

     

     

    CUSIP No.  59564R708   13G   Page 3 of 5 Pages

     

    Item 1.

     

      (a) Name of Issuer:

     

    Biodexa Pharmaceuticals PLC

     

     

    (b)

     

    Address of Issuer’s Principal Executive Offices:

     

    1 Caspian Point

    Caspian Way

    Cardiff, CF10 4DQ, United Kingdom

     

    Item 2.

     

    (a)  Name of Person Filing:
       
      Mercer Street Global Opportunity Fund, LLC
       
    (b)   Address of Principal Business Office or, if none, Residence:
       
     

    1111 Brickell Avenue

    Suite 2920

    Miami, FL 33131

       
    (c) Citizenship:
       
      Delaware
       
    (d) Title of Class of Securities:
       
      Ordinary shares, nominal value £0.001 per share (the “Ordinary Shares”).
       
    (e)  CUSIP Number:
       
       59564R708

     

    Item 3.

     

    Not applicable.

     

     

     

     
     

     

     

     
     CUSIP No. 59564R708   13G   Page 4 of 5 Pages

     

    Item 4. Ownership.

     

    (a)–(c) The information required by Items 4(a)-(c) is set forth in Rows (5)-(9) and Row (11) of the cover page and is incorporated herein by reference.

     

    The percentages used in this Schedule 13G are calculated based on 1,047,806,522 Ordinary Shares outstanding, as reported by the Issuer in the Report of Foreign Private Issuer of Form 6-K filed with the Securities and Exchange Commission on December 21, 2023, after giving effect to the consummation of the offering described therein, and assumes the exercise of the reported warrants held by the Reporting Person, subject to the 9.99% Blocker (as defined below).

     

       

    Jonathan Juchno may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the securities disclosed as owned herein. To the extent Mr. Juchno is deemed to beneficially own such shares, Mr. Juchno disclaims beneficial ownership of these securities for all other purposes.

     

    Pursuant to the terms of certain warrants held by the Reporting Person, the Reporting Person cannot exercise such warrants to the extent the Reporting Person would beneficially own, after such exercise, more than 9.99% of the outstanding Ordinary Shares (the “9.99% Blocker”). The percentage set forth on Row (11) and the number of Ordinary Shares set forth on rows (6), (8) and (9) of the cover page for the Reporting Person give effect to the 9.99% Blocker. Consequently, at this time, the Reporting Person is not able to exercise all the warrants held by the Reporting Person due to the 9.99% Blocker.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.

    Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     
     

     

     

     

    CUSIP No.  59564R708   13G   Page 5 of 5 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

     

       
      By:   MERCER STREET GLOBAL OPPORTUNITY FUND, LLC
         
    January 2, 2024 By: /s/ Jonathan Juchno
        Jonathan Juchno, Authorized representative

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $MTP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MTP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTP
    Financials

    Live finance-specific insights

    See more
    • Midatech Pharma PLC Announces Posting of Circular and Notice of General Meeting

      Proposed Share Consolidation, Authority to Allot Shares, Disapplication of Pre-Emption Rights, Change of Name, Adoption of New Articles and Cancellation of Admission to Trading on AIMABINGDON, OXFORDSHIRE / ACCESSWIRE / March 8, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces, further to the Company's announcements of 9 February and 15 February 2023, that a circular (the "Circular") and formal Notice of General Meeting was posted to shareholders yesterday and will be made available on the Company's website at: www.midatechpharma.com/investors/shareholder-information.The

      3/8/23 2:20:00 AM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Midatech Pharma PLC Announces R&D Programme Focused on Leptomeningeal Disease

      ABINGDON, OXFORDSHIRE / ACCESSWIRE / March 27, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, is pleased to announce a new research programme coded MTD217 focusing on developing new therapeutic options for metastatic cancers with high unmet needs.BackgroundMany cancers exhibit high levels of metabolic plasticity, i.e. the ability to switch between energy-generating pathways in response to cellular stresses[1], such as those caused by chemotherapy. Highly proliferative cancers frequently use the aerobic glycolysis pathway, known as "the Warburg effect", to generate energy2. Oxidat

      3/27/23 8:20:00 AM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Midatech Pharma PLC Announces Results of General Meeting

      Share Consolidation, Change of Name, Adoption of New Articles and Cancellation of Admission to Trading on AIMABINGDON, OXFORDSHIRE / ACCESSWIRE / March 24, 2023 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that at the general meeting of the Company held earlier today (the "General Meeting"), all resolutions put to the Company's shareholders ("Shareholders") were duly passed.The full text of, inter alia, the resolutions proposed and passed at the General Meeting can be found in the Company's Shareholder Circular and Notice of General Meeting (the "Circular") which

      3/24/23 8:00:00 AM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Midatech Pharma PLC Announces Further re: Notice of General Meeting

      Midatech Pharma PLC ("Midatech" or the "Company") Further re: Notice of General Meeting - Correction of Typographical ErrorsABINGDON, OXFORDSHIRE / ACCESSWIRE / March 10, 2023 / Further to the announcement made on 8 March 2023 providing notice of a general meeting (the "GM") of the Company to be held on 24 March 2023, and the publication and despatch of a circular to shareholders containing notice of the resolutions to be considered at the GM (the "Notice") and form of proxy (the "Form of Proxy"), the Company announces the following corrections to certain typographical errors identified within the Notice and Form of Proxy:· Resolution 4 of the Notice ("Resolution 4") refers to a proposed aut

      3/10/23 1:45:00 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTP
    SEC Filings

    See more
    • SEC Form 6-K filed by Midatech Pharma PLC American Depositary Shs

      6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      1/22/24 8:51:48 AM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Midatech Pharma PLC American Depositary Shs

      6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      12/29/23 12:10:19 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Midatech Pharma PLC American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      12/26/23 4:53:52 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Midatech Pharma PLC American Depositary Shs (Amendment)

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      2/14/24 8:47:28 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Midatech Pharma PLC American Depositary Shs (Amendment)

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      2/14/24 2:42:24 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Midatech Pharma PLC American Depositary Shs (Amendment)

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      2/14/24 2:14:48 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTP
    Leadership Updates

    Live Leadership Updates

    See more
    • Midatech Pharma PLC Announces Appointment of Nominated and Financial Adviser

      ABINGDON, UK / ACCESSWIRE / March 8, 2022 / Midatech Pharma PLC ((AIM:MTPH, NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicine, is pleased to announce the appointment of Strand Hanson Limited as the Company's Nominated and Financial Adviser with immediate effect.Turner Pope Investments (TPI) Ltd will be the Company's sole broker.For further information, please contact:Midatech Pharma PLCStephen Stamp, CEO, CFOTel: +44 (0) 29 2048 0180www.midatechpharma.com Strand Hanson Limited (Nominated and Financial Adviser)James Dance / Matthew Chandler / Rob PatrickTel: +44 (0)20 7409 3494 Turner Pope Investments (TPI) Ltd (Broker)Andre

      3/8/22 5:00:00 AM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Midatech Pharma PLC Announces Appointment of Chief Scientific Officer

      Midatech Pharma PLC ('Midatech' or the 'Company') Midatech Strengthens Management Team with Appointment of Dr. Dmitry Zamoryakhin as Chief Scientific OfficerABINGDON, OXFORDSHIRE / ACCESSWIRE / July 12, 2021 / Midatech Pharma PLC ((AIM:MTPH, NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces the appointment of Dr. Dmitry Zamoryakhin as Chief Scientific Officer, a non-board role, with immediate effect.Dr. Zamoryakhin has broad experience across all phases of development of drugs and medical devices, working with regulatory authorities including the EMA, FDA, PMDA, and NMPA. Most recently, he was Chief Medical Offic

      7/12/21 9:50:00 AM ET
      $MTP
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care